Abbvie Inc SEC Filings

The Vanguard Group filed Amendment No. 12 to a Schedule 13G/A reporting 0% ownership of AbbVie Inc. The filing states an 0 amount of common shares beneficially owned and shows 0% of the class. The filing explains an internal realignment completed January 12, 2026 that caused certain Vanguard subsidiaries/divisions to report separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.

AbbVie Inc. has released its 2026 proxy statement for the May 8, 2026 virtual annual meeting, asking stockholders to elect four Class II directors, ratify Ernst & Young as auditor, approve executive pay on an advisory basis, and back a management proposal to eliminate supermajority voting. The board recommends voting against a stockholder proposal seeking an independent board chair.

The proxy highlights 2025 total net revenues of $61.2BN, growth platform net revenues of $56.6BN, and operating cash flow of $19.0BN, along with 12 blockbuster products and about 90 active clinical and device programs. Over the last decade, AbbVie reports a market capitalization increase of $309BN, quarterly dividend growth from $0.57 to $1.73 per share, and total stockholder return of +485%, outpacing the S&P 500 and NYSE Arca Pharmaceutical Index.

The board emphasizes strong governance and ESG practices, including a majority-independent board with a lead independent director, clawback, anti-hedging and anti-pledging policies, and proxy access. Executive pay is described as heavily performance-based, with more than three-fourths of named executive officer compensation tied to non-GAAP financial, strategic, and long-term equity incentives aligned with stockholder returns.

AbbVie Inc. senior vice president and controller David Ryan Purdue reported a routine tax-related share disposition. On February 27, 2026, 2,108 shares of AbbVie common stock were withheld at $232.08 per share to cover tax obligations, a non-market transaction coded as a tax-withholding disposition.

After this event, Purdue directly held 8,468 shares of AbbVie common stock. He also had an additional 543 shares held indirectly through a profit sharing trust tied to an AbbVie savings program, with that balance stated as of February 20, 2026 and including shares from dividend reinvestment.

AbbVie Inc. is soliciting votes for its 2026 Annual Meeting of Stockholders to be held virtually on May 8, 2026 for holders of record as of March 9, 2026. The proxy lists five voting items: election of directors; ratification of Ernst & Young LLP as independent auditor; an advisory "say on pay" for executive compensation; a management proposal to eliminate supermajority voting thresholds; and a stockholder proposal requesting an independent board chair. The proxy highlights 2025 operational and financial metrics, including $61.2BN total net revenues, $56.6BN growth platform net revenues, $19.0BN operating cash flow, $13.8BN adjusted R&D investment, and a +8.5% operational growth figure. It also cites long-term shareholder returns: +485% total stockholder return over 10 years and a +$309BN increase in market capitalization (as of 12/31/2025). The proxy describes board composition, recent leadership changes including Mr. Robert A. Michael serving as CEO and Chair, governance practices, ESG oversight and disclosures, director nominee biographies, director compensation, securities ownership tables, and the Compensation Discussion and Analysis for named executive officers.

AbbVie Inc. senior vice president and controller David Ryan Purdue sold 5,230 shares of AbbVie common stock in an open-market transaction at $233.56 per share on March 4, 2026. After the sale, he directly held 2,654 shares.

A separate entry shows 543 AbbVie shares held directly in an AbbVie Savings program as of February 20, 2026, with that balance including shares acquired through a dividend reinvestment feature.

Morgan Stanley Smith Barney LLC submitted a Form 144 notice concerning proposed sales of Common shares of ABBV (listed NYSE). The filing lists multiple tranches of Restricted Stock and Performance Shares with date labels and per‑lot quantities such as 426, 392, 377, 293, 386, 496, 1,543, and 1,317. The cover shows a filing date of 03/04/2026.

AbbVie Inc. executive Demetris D. Crum, EVP and Chief HR Officer, reported a tax-related share disposition. On February 27, 2026, Crum disposed of 1,594 shares of AbbVie common stock at $232.08 per share to satisfy tax withholding obligations, a non‑open‑market transaction coded as a tax‑withholding disposition. After this event, Crum directly owned 7,914 AbbVie shares.

AbbVie Inc. completed an underwritten public offering of multiple series of senior unsecured notes. The company issued senior floating rate notes due 2028 with an aggregate principal amount of $750,000,000, along with several series of fixed-rate senior notes maturing between 2028 and 2066.

The fixed-rate series include $1,500,000,000 of 3.775% notes due 2028, $1,250,000,000 of 4.125% notes due 2031, $1,250,000,000 of 4.400% notes due 2033, $1,500,000,000 of 4.750% notes due 2036, $1,250,000,000 of 5.550% notes due 2056, and $500,000,000 of 5.650% notes due 2066. All notes rank equally with AbbVie’s other unsecured, unsubordinated obligations.

The notes were issued under an existing shelf registration and an indenture that includes customary covenants, such as limits on certain liens and restrictions on mergers or transfers of substantially all assets. AbbVie has various optional redemption rights, including make-whole redemptions and par calls after specified dates for each longer-dated series.

AbbVie Inc. executive Roopal Thakkar reported a tax-related share disposition. On February 27, 2026, 8,037 shares of AbbVie common stock were disposed of at $232.08 per share to cover tax obligations, leaving 52,376 directly held shares. The filing also reports 2,998 shares held indirectly through a profit sharing trust, reflecting the balance in the AbbVie Savings program as of February 20, 2026, including dividend reinvestment shares that were previously omitted from an earlier Form 3.